Edition:
India

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

2.66USD
17 Jun 2019
Change (% chg)

$0.22 (+9.02%)
Prev Close
$2.44
Open
$2.44
Day's High
$2.67
Day's Low
$2.41
Volume
888,274
Avg. Vol
883,140
52-wk High
$7.34
52-wk Low
$2.21

Latest Key Developments (Source: Significant Developments)

TherapeuticsMD Says Net Revenues For Q1 2019 Were About $3.9 Mln, Compared With Net Revenues Of About $3.8 Mln
Tuesday, 7 May 2019 

May 6 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.16.Q1 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.NET REVENUES FOR Q1 OF 2019 WERE APPROXIMATELY $3.9 MILLION, COMPARED WITH NET REVENUES OF APPROXIMATELY $3.8 MILLION.  Full Article

TherapeuticsMD Signs Commitment Letter For $300 Mln Non-Dilutive Term Loan Financing With TPG Sixth Street Partners
Wednesday, 17 Apr 2019 

April 17 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD SIGNS BINDING COMMITMENT LETTER FOR $300 MILLION NON-DILUTIVE TERM LOAN FINANCING FACILITY WITH TPG SIXTH STREET PARTNERS.THERAPEUTICSMD INC - ADDITIONAL NON-DILUTIVE FUNDING WILL SUPPORT LAUNCHES OF BIJUVA(TM) AND ANNOVERA(TM).THERAPEUTICSMD INC - BORROWINGS UNDER TSSP TERM LOAN FACILITY WILL ACCRUE INTEREST AT 3-MONTH LIBOR PLUS 7.75%.  Full Article

TherapeuticsMD Announces FDA Approval Of Bijuva Capsules For Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause
Monday, 29 Oct 2018 

Oct 29 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES FDA APPROVAL OF TX-001HR: BIJUVA™ (ESTRADIOL AND PROGESTERONE) CAPSULES FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE.THERAPEUTICSMD INC - BIJUVA IS EXPECTED TO BE AVAILABLE IN PHARMACIES IN Q2 OF 2019.THERAPEUTICSMD INC - BIJUVA IS EXPECTED TO BE AVAILABLE IN PHARMACIES IN Q2 OF 2019.  Full Article

Therapeuticsmd Files For Potential Mixed Shelf Offering
Wednesday, 1 Aug 2018 

July 31 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership
Wednesday, 1 Aug 2018 

July 31 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND THERAPEUTICSMD ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS - CO, THERAPEUTICSMD ENTERED LICENSING AGREEMENT THAT GRANTS CO RIGHTS TO COMMERCIALIZE TX-004HR AND TX-001HR IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - WILL PAY THERAPEUTICSMD A MILESTONE FEE UPON FIRST REGULATORY APPROVAL IN CANADA OF EACH OF TX-004HR AND TX-001HR.KNIGHT THERAPEUTICS - AGREED TO INVEST $20 MILLION IN THERAPEUTICSMD COMMON STOCK ALONG WITH CLOSING OF PUBLIC OFFERING OF THERAPEUTICSMD COMMON STOCK.  Full Article

TherapeuticsMD Announces Q2 Financial Results
Monday, 30 Jul 2018 

July 30 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.15.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $3.8 MILLION VERSUS I/B/E/S VIEW $4.2 MILLION.PDUFA TARGET ACTION DATE OF OCTOBER 28, 2018 FOR TX-001HR.ENDED QUARTER WITH APPROXIMATELY $154.4 MILLION IN CASH AND APPROXIMATELY $73.1 MILLION IN OUTSTANDING DEBT.  Full Article

TherapeuticsMD Gets FDA Approval Of TX-004HR IMVEXXY For Treatment Of Moderate To Severe Dyspareunia
Wednesday, 30 May 2018 

May 30 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES FDA APPROVAL OF TX-004HR: IMVEXXY (ESTRADIOL VAGINAL INSERTS), THE LOWEST DOSE VAGINAL ESTROGEN PRODUCT APPROVED FOR THE TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VVA, DUE TO MENOPAUSE.ANTICIPATES THAT IMVEXXY WILL BE AVAILABLE FOR COMMERCIAL DISTRIBUTION IN JULY.AS PART OF FDA'S APPROVAL, THERAPEUTICSMD HAS COMMITTED TO CONDUCT A POST-APPROVAL OBSERVATIONAL STUDY.  Full Article

TherapeuticsMD Submits New Drug Application For TX-001HR
Friday, 29 Dec 2017 

Dec 28 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR.THERAPEUTICSMD - EXPECTS TO LEARN OF ACCEPTANCE OF NDA FROM FDA ABOUT 74 DAYS AFTER NDA SUBMISSION.  Full Article

Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Therapeuticsmd Inc ::THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR.THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE SET OF MAY 29, 2018.THERAPEUTICSMD INC - COMPANY CURRENTLY PLANS TO LAUNCH TX-004HR IN Q3 OF 2018 IF APPROVAL OCCURS ON OR BEFORE PDUFA TARGET ACTION DATE.  Full Article

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR TX-004HR.THERAPEUTICSMD INC - COMPANY EXPECTS TO LEARN OF ACCEPTANCE OF NDA RESUBMISSION WITHIN 30 CALENDAR DAYS.  Full Article